XML 56 R19.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

GOODWILL AND OTHER INTANGIBLE ASSETS | 12 Months Ended
--- | ---
Oct. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract] |
GOODWILL AND OTHER INTANGIBLE ASSETS | GOODWILL AND OTHER INTANGIBLE ASSETS The following table presents goodwill balances and the movements for each of our reportable segments during the years ended October 31, 2018 and 2019:
| Life Sciences and Applied Markets |  | Diagnostics and Genomics |  | Agilent CrossLab |  | Total
| (in millions)
Goodwill as of October 31, 2017 | $ | 773 |  |  | $ | 1,330 |  |  | $ | 504 |  |  | $ | 2,607 |
Foreign currency translation impact | (7 | ) |  | (4 | ) |  | (4 | ) |  | (15 | )
Goodwill arising from acquisitions | 37 |  |  | 281 |  |  | 63 |  |  | 381 |
Goodwill as of October 31, 2018 | $ | 803 |  |  | $ | 1,607 |  |  | $ | 563 |  |  | $ | 2,973 |
Foreign currency translation impact | (1 | ) |  | (2 | ) |  | (2 | ) |  | (5 | )
Goodwill arising from acquisitions and adjustments | 636 |  |  | (11 | ) |  | — |  |  | 625 |
Goodwill as of October 31, 2019 | $ | 1,438 |  |  | $ | 1,594 |  |  | $ | 561 |  |  | $ | 3,593 |
As of September 30, 2019, our annual impairment test date, we assessed goodwill impairment for our reporting units and no impairment was indicated. The component parts of other intangible assets at October 31, 2018 and 2019 are shown in the table below:
| Other Intangible Assets
| Gross Carrying Amount |  | Accumulated Amortization and Impairments |  | Net Book Value
| (in millions)
As of October 31, 2018: |  |  |  |  |
Purchased technology | $ | 947 |  |  | $ | 683 |  |  | $ | 264 |
Trademark/Tradename | 151 |  |  | 88 |  |  | 63 |
Customer relationships | 107 |  |  | 63 |  |  | 44 |
Third-party technology and licenses | $ | 28 |  |  | $ | 19 |  |  | $ | 9 |
Total amortizable intangible assets | $ | 1,233 |  |  | $ | 853 |  |  | $ | 380 |
In-Process R&D | 111 |  |  | — |  |  | 111 |
Total | $ | 1,344 |  |  | $ | 853 |  |  | $ | 491 |
As of October 31, 2019: |  |  |  |  |
Purchased technology | $ | 1,413 |  |  | $ | 763 |  |  | $ | 650 |
Backlog | 5 |  |  | 5 |  |  | — |
Trademark/Tradename | 196 |  |  | 102 |  |  | 94 |
Customer relationships | 329 |  |  | 87 |  |  | 242 |
Third-party technology and licenses | $ | 28 |  |  | $ | 22 |  |  | $ | 6 |
Total amortizable intangible assets | $ | 1,971 |  |  | $ | 979 |  |  | $ | 992 |
In-Process R&D | 115 |  |  | — |  |  | 115 |
Total | $ | 2,086 |  |  | $ | 979 |  |  | $ | 1,107 |
In 2019, we acquired two businesses, BioTek and ACEA, for a combined purchase price of approximately $1.4 billion. See Note 3, "Acquisitions", for additional information. During fiscal year 2019, w e recorded additions to goodwill of $636 million and to other intangible assets of $744 million related to the acquisition of ACEA and BioTek. In the second quarter of fiscal year 2019, we recorded a measurement period adjustment to goodwill of $11 million for deferred tax assets related to pre-acquisition net operating losses of Advanced Analytical Technologies, Inc. The increase to other intangible assets due to foreign currency translation was not material in 2019. During fiscal year 2018, we recorded additions to goodwill of $381 million and to intangible assets of $262 million related to the acquisition of seven businesses. During the year other intangible assets decreased $1 million, due to the impact of foreign exchange translation. In general, for United States federal tax purposes, goodwill from asset purchases is amortizable however any goodwill created as part of a stock acquisition is not deductible. In 2019, there were no impairments of other intangible assets recorded. During 2018, we recorded an impairment charge of $21 million related to purchased intangible assets within the diagnostics and genomics segment that were deemed unrecoverable. In 2017, there were no impairments of other intangible assets recorded. Amortization expense of intangible assets was $128 million in 2019, $110 million in 2018, and $120 million in 2017. Future amortization expense related to existing finite-lived purchased intangible assets associated with business combinations for the next five fiscal years and thereafter is estimated below:
Estimated future amortization expense: |
| (in millions)
2020 | $ | 186 |
2021 | $ | 172 |
2022 | $ | 150 |
2023 | $ | 107 |
2024 | $ | 86 |
Thereafter | $ | 291 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration